Cellino's iPSC Manufacturing Technology Receives FDA Advanced Manufacturing Technology (AMT) Designation
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cellino, a leader in advanced biomanufacturing, today announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA's Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER). This prestigious designation highlights the transformative potential of Cellino's automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies.
The FDA encourages the adoption of advanced manufacturing technologies (AMTs) that improve manufacturing reliability, product quality, and production scale. The AMT designation accelerates timelines for therapies manufactured using Cellino's optical biomanufacturing technology, offering higher priority within the FDA, along with earlier and more frequent interactions during Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) processes for a faster path to market.
'We are honored to receive the AMT designation for our proprietary technology stack,' said Nabiha Saklayen, Ph.D., CEO and Co-Founder of Cellino. 'This recognition affirms our commitment to revolutionizing the production of patient-specific iPSCs, enabling faster and more consistent clinical and commercial-scale manufacturing. It's a pivotal moment in our mission to deliver personalized regenerative therapies that can scale globally, transforming healthcare for millions.'
Autologous iPSC manufacturing has long been one of the most complex challenges in biomanufacturing, involving labor-intensive processes like manual passaging and colony picking that only a limited number of experts worldwide can perform. These hurdles have slowed progress, preventing many therapeutic programs from advancing past early-phase clinical trials. Cellino's proprietary optical bioprocessing technology overcomes these challenges by introducing precision, reproducibility, and scalability, ensuring reliable, high-quality iPSC production for both clinical trials and commercial stages.
'This AMT designation underscores the scientific rigor and transformative potential of our technology,' said Marinna Madrid, Ph.D., Chief Product Officer and Co-Founder of Cellino. 'Automated, optical manufacturing is key to ensuring patient access to regenerative medicines. This milestone brings us closer to scaling therapies from Phase 1 through large-scale commercialization, aiming to address some of the world's most debilitating chronic degenerative diseases.'
Cellino intends to leverage the AMT designation to expedite the translation of personalized iPSC-derived therapies into clinical practice. With global chronic disease burdens rising and more than 100 million individuals in the U.S. alone who could potentially benefit from iPSC-derived therapies, Cellino's technology is poised to significantly expand patient access to next-generation living medicines.
For more information on the FDA's Advanced Manufacturing Technologies Designation Program, visit the FDA AMT Guidance.
About Cellino
Cellino is a leader in advanced biomanufacturing technology, committed to making personalized cell, tissue, and organ replacements a reality for patients around the world. Learn more at www.cellinobio.com and follow us on LinkedIn and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
Coeur to Participate in the RBC Capital Markets Global Mining & Materials Conference
CHICAGO--(BUSINESS WIRE)--Coeur Mining, Inc.'s ('Coeur' or the 'Company') (NYSE: CDE) Chairman, President and Chief Executive Officer, Mitchell J. Krebs, and Senior Vice President and Chief Financial Officer, Thomas S. Whelan, will participate in the RBC Capital Markets Global Mining & Materials Conference in New York, New York on Thursday, June 12, 2025. The RBC Capital Markets Global Mining & Materials Conference is an invitation-only investment conference. Presentation materials will be made available on the Company's website at About Coeur Coeur Mining, Inc. is a U.S.-based, well-diversified, growing precious metals producer with five wholly-owned operations: the Las Chispas silver-gold mine in Sonora, Mexico, the Palmarejo gold-silver complex in Chihuahua, Mexico, the Rochester silver-gold mine in Nevada, the Kensington gold mine in Alaska and the Wharf gold mine in South Dakota. In addition, the Company wholly-owns the Silvertip polymetallic critical minerals exploration project in British Columbia.
Business Wire
29 minutes ago
- Business Wire
CFP Board Convenes AI Working Group
WASHINGTON--(BUSINESS WIRE)--CFP Board is convening an AI Working Group on June 10-11 at its Washington, D.C., headquarters to explore how artificial intelligence is transforming the financial planning ecosystem and to define the evolving role of human expertise in a tech-powered future. As part of CFP Board's broader strategy to help the profession thrive in an AI-powered world, the group is developing strategic, actionable recommendations to guide the profession forward, helping ensure that technology enhances the human relationships at the core of financial planning. 'AI is not a distant wave. It's already reshaping client expectations and how advisors deliver value,' said CFP Board CEO Kevin R. Keller, CAE. 'CFP Board is taking the lead to help the profession harness AI's potential to elevate financial planning and strengthen engagement.' In partnership with consulting company Heidrick & Struggles and led by CFP Board COO K. Dane Snowden, the AI Working Group brings together financial and technology leaders to explore how the financial planning profession can rise to meet the challenges and opportunities of an AI-driven future. The group is examining emerging trends, real-world use cases and ethical considerations shaping AI adoption across the profession. From enhancing client experiences and streamlining advisor workflows to protecting public trust, the conversations reflect both the complexity and the promise of this pivotal moment. Discussion topics include the Current State of AI, Regulation and The Financial Planner Lens, as well as exercises on exploring future scenarios and evaluating key stakeholder implications. The AI Working Group includes the following members: Andrew Altfest, CFP ®, MBA, Founder and CEO, FP Alpha and President, Altfest Personal Wealth Management Joel Bruckenstein, CFP ®, CMFC, CFS, President, T3 Technology Alan Davidson, former Assistant Secretary of Commerce and Administrator, National Telecommunications and Information Administration Tristan Fischer, Managing Director, Financial Services Consulting, Ernst & Young LLP Tim Foley, Head of Artificial Intelligence Accelerator, LPL Financial David Goldberg, Senior Vice President, Chief Data and Analytics Officer, Edelman Financial Engines Brooke Juniper, CFA ®, CAIA ®, Chief Executive Officer, Sage Trent Mumma, Chief Product Officer, Orion Advisor Solutions Celeste Revelli, CFP ®, BFA ™, CSM ®, CSPO ®, Vice President of Financial Planning Technology, Fidelity Institutional ® (FI) Noah Rosenberg, Chief Financial Officer, Morning Consult Apoorv Saxena, Managing Director, Head of AI/Data Driven Value Creation, Silver Lake Megan Shearer, Ph.D., Senior Data Scientist, Janus Henderson Zar Toolan, General Partner, Head of Data & AI, Edward Jones Brian Walsh, Ph.D., CFP ®, Head of Advice & Planning, SoFi For more information on using AI in financial planning, download CFP Board's Generative AI Ethics Guide, which provides a framework for CFP ® professionals to integrate AI into their practices ethically. ABOUT CFP BOARD CFP Board is the professional body for personal financial planners in the U.S. CFP Board consists of two affiliated organizations focused on advancing the financial planning profession for the public's benefit. CFP Board of Standards sets and upholds standards for financial planning and administers the prestigious CERTIFIED FINANCIAL PLANNER ® certification — widely recognized by the public, advisors and firms as the standard for financial planners — so that the public has access to the benefits of competent and ethical financial planning. CFP ® certification is held by more than 100,000 people in the U.S. CFP Board Center for Financial Planning addresses diversity and workforce development challenges and conducts and publishes research that adds to the financial planning profession's body of knowledge.
Business Wire
31 minutes ago
- Business Wire
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus' or the 'Company'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million Full year fiscal 2025 revenue is expected to range between $76 million and $80 million The third quarter fiscal 2025 revenue range set forth above is preliminary, unaudited, based on currently available information, and subject to adjustment in the final financial statements to be filed with the Company's Quarterly Report on Form 10-Q for the third quarter fiscal 2025, expected to be filed July 2, 2025. Full year fiscal 2025 revenue guidance may also be adjusted when the Company reports third quarter fiscal 2025 results. 'Market uncertainties surrounding future funding, drug pricing and potential tariffs are creating significant headwinds for both our pharmaceutical and biotech clients, resulting in budget reductions, project cancellations, and delays that are more pronounced than what we have experienced over the past two years,' said Shawn O'Connor, Chief Executive Officer of Simulations Plus. 'While our software segment has remained relatively resilient, given its role as critical infrastructure in drug development programs, demand for services has proven more sensitive to market volatility and is coming in below our expectations. 'To better position the Company for long-term alignment with our clients, we recently announced a strategic reorganization—transitioning from a business unit structure to a functionally driven operating model. We also made key leadership appointments to enhance client engagement and elevate our sales and marketing capabilities. 'These actions mark the final phase of a multi-year transformation aimed at streamlining operations, unlocking synergies across teams, and concentrating our resources on the most promising growth opportunities. We believe the new organizational structure will also foster greater collaboration through centralized product and technology development, contributing to accelerated delivery of software enhancements, platform integration, and AI advancements. 'Finally, these changes are expected to improve operational efficiency and better position us for sustainable and profitable long-term growth. Looking ahead, we remain optimistic about the future of predictive analytics in biosimulation and clinical operations. These capabilities are essential to helping our clients achieve greater efficiency and success, and we are proud to be a long-standing partner and innovation leader in this space,' concluded O'Connor. Third Quarter Fiscal 2025 Press Release, Webcast, and Conference Call Details The Company will report third quarter fiscal 2025 financial results after the market close on Wednesday, July 2, 2025. Shawn O'Connor, Chief Executive Officer, and Will Frederick, Chief Financial Officer, will host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss the details of Simulations Plus' performance for the quarter and certain forward-looking information. The call may be accessed by registering here or by calling 1-877-451-6152 (domestic) or 1-201-389-0879 (international). The webcast can be accessed on the investor relations page of the Simulations Plus website where it will also be available for replay approximately one hour following the call. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Preliminary Financial Results and Financial Guidance The preliminary financial results set forth above for the third quarter fiscal 2025 reflect preliminary, unaudited estimates with respect to such results based solely on currently available information, which is subject to change. Such preliminary results are subject to the finalization of quarter-end financial and accounting procedures. While carrying out such procedures, Simulations Plus may identify items that would require it to make adjustments to the preliminary estimates of financial results set forth herein. As a result, our actual financial results could differ than the information set forth herein and such differences could be material. Preliminary results should not be viewed as a substitute for our full quarterly financial statements for the three months ended May 31, 2025, which are being prepared in accordance with U.S. GAAP. In addition, full year fiscal 2025 revenue guidance should not be viewed as a substitute for full financial statements prepared in accordance with GAAP. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward looking statements contained in this press release include, but are not limited to, the quotation of our Chief Executive Officer relating to our future performance and growth, statements relating to full fiscal year 2025 revenue guidance and other statements about future events. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
